IRCCS Azienda Ospedaliero-Universitaria di Bologna at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
IRCCS Azienda Ospedaliero-Universitaria di Bologna brings 2 presentations to ASH 2026 in New Orleans. Its program covers BCMA-targeted bispecific antibodies in myeloma and ways to prevent progression and resistance in myeloproliferative neoplasms. It also looks at antibody-drug conjugates that deliver targeted payloads in childhood AML.
| Organization | ASH 2026 Attendance |
|---|---|
IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna, Italy | |
University of Bologna teaching hospital, the Sant'Orsola Polyclinic, home of the Seràgnoli Institute of Hematology. | Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Talk Preventing Progression and Overcoming Resistance in MPNs Moving myeloproliferative neoplasm care toward earlier disease-modifying therapy and molecular monitoring, and handling resistance to Janus kinase inhibitors. |
Instantly find 20 buyers from IRCCS Azienda Ospedaliero-Universitaria di Bologna
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction